The DrBioRight system goes beyond NLP to produce "natural-language understanding" through AI as it creates automated dialog with researchers to speed up data analysis.
TargetCancer is activating two enrollment sites and setting up a remote consenting process so patients with rare cancers can be seen at local community hospitals.
Two studies presented at ASCO's virtual annual meeting demonstrated the clinical utility of germline findings in guiding treatment decisions in cancer.
Integrated analyses uncovered recurrent changes in renal medullary carcinoma, including potential treatment vulnerabilities stemming from DNA replication stress.
A single-cell "atlas" of pathologically normal breast tissue was presented by an MD Anderson Cancer Center representative at the AACR's online annual meeting this week.
